Medical News

RSS

National Kickoff Classic partners with Close the Gap campaign to raise heart disease risk factor awareness

Boston Scientific today announced that its Close the Gap campaign is partnering with the Kirk Herbstreit National Kickoff Classic to raise awareness of heart disease risk factors for women and minorities.

26 Aug 2010

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

China PharmaHub Corp. ("PharmaHub"), which has recently merged with World Wide Relics which has changed its name to China PharmaHub Corp, and is in the process of obtaining approval from FINRA to trade under its new name with a new symbol, announced today that it has signed an Exclusive Distribution Agreement ("Agreement") with a world leader in precision glass technology which can be utilized to manufacture high precision radioactive glass spheres that emit alpha, beta or gamma radiation, either individually or in combination, for the treatment of malignant tumors of the liver.

26 Aug 2010

Aethlon Medical receives approval for Chronic HCV Infection treatment

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Medanta Independent Ethics Committee (MIEC) at Medanta, The Medicity Institute (Medicity) has approved a treatment program entitled "Use of the Aethlon Hemopurifier in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy."

26 Aug 2010

American HomePatient announces extension of self-tender offer

American HomePatient, Inc., one of the nation's largest home health care providers, today announced that it is extending its previously announced self-tender offer for all outstanding shares of common stock of the Company at $0.67 per share, until 5:00 P.M., New York City time, Wednesday, September 1, 2010, unless the tender offer is further extended.

26 Aug 2010

Amneal Pharmaceuticals receives FDA approval for Spironolactone HCl tablets

Amneal Pharmaceuticals, LLC is pleased to announce that it has received U.S. FDA approval to manufacture Spironolactone HCl tablets in 25 mg, 50 mg and 100 mg strengths effective July 2, 2010.

26 Aug 2010

Sonomax Technologies 2010 second quarter revenue increases to $328,980

Sonomax Technologies Inc. today disclosed its results for the three and six month periods ended June 30, 2010.

26 Aug 2010

Laxai Pharma reports $1,735K revenue for first six months

Laxai Pharma, Ltd. an international pharmaceutical contract research organization ("CRO"), is pleased to announce that it has published its second quarter results last week for the period ended as of June 30, 2010.

26 Aug 2010

Sanctions on Shalom Toowoomba nursing home due to inadequate aged care

A nursing home in Toowoomba in southern Queensland has been sanctioned for a serious breaches in its healthcare and safety measures. The Shalom Toowoomba Nursing Home has been warned by the federal Department of Ageing that its care of patients is so poor it will not receive Commonwealth subsidies for six months. The Department would be making daily inspections to make sure the breaches are being fixed.

26 Aug 2010

NSW bed sore death could have been prevented: Coroner

After the death of a severely disabled woman in New South Wales, the coroner has ruled that the death due to bed sores was avoidable and caregivers need more training to manage such cases. 26-year-old Kate Therese Bugmy died at Broken Hill Base Hospital in June 2007 as a result of sepsis from bed sores. She had severe cerebral palsy, epilepsy and an intellectual disability and weighed just 36 kilos when she died.

26 Aug 2010

Seven year Aspirin for cancer trial

A large clinical trial looking at the cancer preventive actions of aspirin is underway. The seven year study will include six regional centers from Victoria including Ballarat, Bendigo, Geelong, Warrnambool, Traralgon and Shepparton. The ASPirin for Reducing Events in the Elderly (ASPREE) study will involve about 19,000 participants from Australia and the United States.

26 Aug 2010

Practice guideline-recommended care reduces bleeding in cirrhosis patients

Compliance with practice guideline-recommended treatment for cirrhosis is associated with a reduction in first esophageal variceal hemorrhage (EVH; bleeding), according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

26 Aug 2010

AARP Report finds increase in brand-name drug costs outstrips inflation

"Retail prices for some of the most widely used brand-name prescription drugs shot up more than 8 percent in 2009, even as inflation plummeted to a record low, according to a new AARP analysis of retail drug price trends released today.

26 Aug 2010

Health on the Hill – August 25, 2010

In this Kaiser Health News discussion, KFF's Jackie Judd talks with Time's Michael Crowley about recent news during this August recess. Lawmakers are finding the electorate to be quieter on the topic of health care than they were during last summer's heated town hall meetings.

26 Aug 2010

Lotus Pharmaceuticals initiates R-Bambuterol Clinical Trial I on-schedule

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China, announced today that it has entered R-Bambuterol Clinical Trial I on-schedule and is on-track to complete in six months. The studies will evaluate the safety and tolerability of the new drug as well as the biological activity by measuring responses in healthy volunteers.

26 Aug 2010

BioTrends Research Group report provides in-depth view of kidney transplantation market

BioTrends Research Group, Inc. recently published its TreatmentTrends: Kidney Transplantation report. This report is based on online survey results from over 150 physicians (general nephrologists, transplant nephrologists and transplant surgeons). It provides an in-depth view of the kidney transplantation market, including the roles of the various specialties, promotional efforts and sales representative messaging, barriers to kidney transplant, the care of post-transplant patients, and current and projected use of immunosuppressive agents for induction, maintenance and acute rejection.

26 Aug 2010

Queen West Village Family Health Team to provide primary health care for community

Toronto's Queen West neighbourhood and the province's health care system alike will benefit from the August 24 announcement that a Family Health Team will be housed locally at the Centre for Addiction and Mental Health.

26 Aug 2010

DTC grants eligibility status to Medisafe 1 Technologies

Medisafe 1 Technologies Corp., a developer of a U.S. patented technology that physically prevents unauthorized administration of prescription medications, announced today that the company has been granted eligibility status by the Depository Trust Company. The DTC provides banks, brokerage firms and other institutions with an efficient means of moving securities and settling trades electronically.

26 Aug 2010

New book on fighting hair loss

World renowned hair loss expert, Dr. Larry Shapiro, announced the release of his new book, Fight Hair Loss and Win! and says that Elin Nordegren is not alone when it comes to hair loss as a result of stress. Shapiro says millions of women and men are experiencing the same and that heightened levels of stress, popular nutritional supplements, hormonal imbalances and many other unsuspecting factors are now linked to hair loss.

26 Aug 2010

Bio-Reference Laboratories third-quarter revenues increase 25% to $121,719

Bio-Reference Laboratories, Inc. (Except for Per Share Data or where otherwise noted, numbers are in thousands) announced that the Company recorded current quarter revenues of $121,719, the best ever quarter in terms of revenues in corporate history and an increase of 25% over the $97,424 recorded in the third quarter, fiscal year 2009.

26 Aug 2010

Preferred Imaging installs Naviscan Positron Emission Mammography scanner in new Plano facility

Preferred Imaging Centers has installed the Naviscan PEM scanner into its newest facility in Plano, TX, adding a dedicated breast imaging modality to its array of diagnostic tools. PEM (Positron Emission Mammography) scanners are high-resolution breast PET systems that show the location as well as the metabolic phase of a lesion. The metabolic view assists physicians in making the optimal patient care decision by providing an unprecedented ability to distinguish between benign and malignant lesions, what researchers term “specificity.”

26 Aug 2010